학술논문

Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data up to 24 Months
Document Type
Journal
Source
HUMAN GENE THERAPY; OCT 1 2021, 32 19-20, pA107-pA107, 1p.
Subject
Language
English
ISSN
15577422